Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?
01:00pm, Monday, 01'st Jun 2020
Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020.
Will Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Spend Its Cash Wisely?
10:53am, Thursday, 28'th May 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
12:05pm, Wednesday, 27'th May 2020
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and.
Stocks Trading Above 52 Week Low and Below 52 Week High: $IOVA $CRBP $FATE
02:15pm, Monday, 25'th May 2020
May 25, 2020 (The Market Signal via Comtex) --
Sector Reports was created as a platform to help investors find the best free Stock Reports on stocks they...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
12:05pm, Friday, 22'nd May 2020
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of.
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
Edited Transcript of CRBP earnings conference call or presentation 11-May-20 12:30pm GMT
07:09am, Monday, 18'th May 2020
Q1 2020 Corbus Pharmaceuticals Holdings Inc Earnings Call
Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Friday, 15'th May 2020
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
12:05pm, Friday, 15'th May 2020
Norwood, MA, May 15, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering.
Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?
01:30pm, Thursday, 14'th May 2020
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates
01:55pm, Monday, 11'th May 2020
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 0.00% and 7.44%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
11:05am, Monday, 11'th May 2020
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
12:05pm, Monday, 04'th May 2020
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”.
